Key facts
- This page summarizes Phuong Khanh Morrow's Form 4 filing for CRISPR Therapeutics AG (CRSP).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 May 2023, 17:35.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Tax liability
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on May 23, 2023, (ii) one quarter of the shares shall vest on May 23, 2024, (iii) one quarter of the shares shall vest on May 23, 2025, and (iv) one quarter of the shares shall vest on May 23, 2026.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Footnote F3
On May 23, 2022, the reporting person was granted 27,750 restricted stock units. On May 23, 2023, 6,938 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.